CO6270207A2 - Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]metil]fenil-2e-2-propenamida y procedimientos para su preparacion - Google Patents
Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]metil]fenil-2e-2-propenamida y procedimientos para su preparacionInfo
- Publication number
- CO6270207A2 CO6270207A2 CO10035474A CO10035474A CO6270207A2 CO 6270207 A2 CO6270207 A2 CO 6270207A2 CO 10035474 A CO10035474 A CO 10035474A CO 10035474 A CO10035474 A CO 10035474A CO 6270207 A2 CO6270207 A2 CO 6270207A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- methyl
- regulator
- pharmaceutical compositions
- chelator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones farmacéuticas que incluyen un compuesto terapéutico pobremente soluble en agua, un solvente acuoso, un quelante/antioxidante, un regulador del pH o un componente regulador del pH, y un agente de volumen. Las composiciones farmacéuticas pueden ser oralmente ingeridas o se pueden administrar parenteralmente. Las composiciones farmacéuticas se pueden ademas liofilizar para formar una torta farmacéuticamente aceptable que se pueda administrar oralmente, por ejemplo como una forma de dosificacion oral solida; o que se pueda reconstituir y administrar parenteralmente, por ejemplo como un solo bolo intravenoso o una infusion intravenosa, o se puede administrar oralmente, por ejemplo como una solucion para beber. 1.- Una composicion farmacéutica, la cual comprende: N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)-etil]-amino]-metil]-fenil]-2E-2-propenamida, o una sal farmacéuticamente aceptable de la misma; un regulador del pH o un componente regulador del pH; y un agente de volumen. 2.- La composicion de la reivindicacion 1, la cual comprende ademas un quelante/antioxidante. 3.- La composicion de la reivindicacion 1, en donde el agente de volumen mencionado se selecciona a partir de sacarosa, trehalosa, dextrano, y HPbCD. 4.- La composicion de la reivindicacion 2, en donde el quelante/antioxidante mencionado es EDTA disodica. 5.- La composicion de la reivindicacion 1, en donde el regulador del pH o el componente del regulador del pH mencionado se selecciona a partir de un regulador de lactato o acido lactico, un regulador de fosfato o acido fosforico, y una combinacion de ambos. 6.- La composicion de la reivindicacion 1, en donde esta composicion forma una torta farmacéuticamente aceptable después de la liofilizacion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97383007P | 2007-09-20 | 2007-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270207A2 true CO6270207A2 (es) | 2011-04-20 |
Family
ID=40005335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10035474A CO6270207A2 (es) | 2007-09-20 | 2010-03-25 | Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]metil]fenil-2e-2-propenamida y procedimientos para su preparacion |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20100331387A1 (es) |
| EP (1) | EP2205222A1 (es) |
| JP (1) | JP2010540445A (es) |
| KR (1) | KR20100059887A (es) |
| CN (1) | CN101801345A (es) |
| AR (1) | AR068822A1 (es) |
| AU (1) | AU2008302273A1 (es) |
| BR (1) | BRPI0817118A2 (es) |
| CA (1) | CA2696914A1 (es) |
| CL (1) | CL2008002786A1 (es) |
| CO (1) | CO6270207A2 (es) |
| EC (1) | ECSP10010039A (es) |
| GT (1) | GT201000062A (es) |
| MA (1) | MA31744B1 (es) |
| MX (1) | MX2010002970A (es) |
| PE (1) | PE20090706A1 (es) |
| RU (1) | RU2010115262A (es) |
| TN (1) | TN2010000097A1 (es) |
| TW (1) | TW200930416A (es) |
| WO (1) | WO2009039226A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2743740T3 (es) * | 2016-03-31 | 2020-02-20 | Midatech Ltd | Aducto de ciclodextrina-panobinostat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US7250514B1 (en) * | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| ES2297490T3 (es) * | 2003-07-23 | 2008-05-01 | Bayer Pharmaceuticals Corporation | Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones. |
| US20060270730A1 (en) * | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| US20060128660A1 (en) * | 2004-12-10 | 2006-06-15 | Wisconsin Alumni Research Foundation | FK228 analogs and methods of making and using the same |
| WO2006094068A2 (en) * | 2005-03-01 | 2006-09-08 | The Regents Of The University Of Michigan | Hdac inhibitors that promote brm expression and brm related diagnostics |
| BRPI0806341A2 (pt) * | 2007-01-10 | 2011-09-06 | Novartis Ag | formulações de inibidores de desacetilase |
| BRPI0807812A2 (pt) * | 2007-02-15 | 2020-06-23 | Novartis Ag | Combinações de lbh589 com outros agentes terapêuticos para tratar câncer |
-
2008
- 2008-09-17 CL CL2008002786A patent/CL2008002786A1/es unknown
- 2008-09-18 WO PCT/US2008/076752 patent/WO2009039226A1/en active Application Filing
- 2008-09-18 CA CA2696914A patent/CA2696914A1/en not_active Abandoned
- 2008-09-18 MX MX2010002970A patent/MX2010002970A/es not_active Application Discontinuation
- 2008-09-18 JP JP2010525936A patent/JP2010540445A/ja active Pending
- 2008-09-18 AU AU2008302273A patent/AU2008302273A1/en not_active Abandoned
- 2008-09-18 EP EP08832517A patent/EP2205222A1/en not_active Withdrawn
- 2008-09-18 CN CN200880107798A patent/CN101801345A/zh active Pending
- 2008-09-18 PE PE2008001634A patent/PE20090706A1/es not_active Application Discontinuation
- 2008-09-18 KR KR1020107006075A patent/KR20100059887A/ko not_active Application Discontinuation
- 2008-09-18 RU RU2010115262/15A patent/RU2010115262A/ru unknown
- 2008-09-18 BR BRPI0817118A patent/BRPI0817118A2/pt not_active IP Right Cessation
- 2008-09-18 US US12/676,755 patent/US20100331387A1/en not_active Abandoned
- 2008-09-18 AR ARP080104055A patent/AR068822A1/es unknown
- 2008-09-19 TW TW097136190A patent/TW200930416A/zh unknown
-
2010
- 2010-02-25 TN TNP2010000097A patent/TN2010000097A1/fr unknown
- 2010-03-12 MA MA32691A patent/MA31744B1/fr unknown
- 2010-03-16 GT GT201000062A patent/GT201000062A/es unknown
- 2010-03-17 EC EC2010010039A patent/ECSP10010039A/es unknown
- 2010-03-25 CO CO10035474A patent/CO6270207A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101801345A (zh) | 2010-08-11 |
| MA31744B1 (fr) | 2010-10-01 |
| TW200930416A (en) | 2009-07-16 |
| AR068822A1 (es) | 2009-12-09 |
| JP2010540445A (ja) | 2010-12-24 |
| GT201000062A (es) | 2012-03-30 |
| KR20100059887A (ko) | 2010-06-04 |
| MX2010002970A (es) | 2010-04-01 |
| CA2696914A1 (en) | 2009-03-26 |
| AU2008302273A1 (en) | 2009-03-26 |
| RU2010115262A (ru) | 2011-10-27 |
| US20100331387A1 (en) | 2010-12-30 |
| WO2009039226A1 (en) | 2009-03-26 |
| EP2205222A1 (en) | 2010-07-14 |
| BRPI0817118A2 (pt) | 2019-09-24 |
| ECSP10010039A (es) | 2010-04-30 |
| CL2008002786A1 (es) | 2009-05-15 |
| TN2010000097A1 (en) | 2011-09-26 |
| PE20090706A1 (es) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6955648B2 (ja) | 異常炎症反応に関連する状態を処置するための方法および組成物 | |
| US20240009113A1 (en) | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose | |
| US20220249463A1 (en) | Methods of altering cardiac remodeling using compounds that promote glucose oxidation | |
| RU2016147575A (ru) | Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции | |
| BR112014016085A2 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
| ES2569391T3 (es) | Tritocualina para uso en el tratamiento de la fibrosis quística | |
| JP2012511034A5 (es) | ||
| ES2960392T3 (es) | Agente terapéutico contra el cáncer | |
| ES2770113T3 (es) | Análogos de la cisteamina resistentes a la ADO y sus usos | |
| JP2009542623A5 (es) | ||
| BR112019010249A2 (pt) | método de tratamento de doença de armazenamento de glicogênio | |
| CN104349780A (zh) | 含有吡罗昔康或其药学上可接受的盐和透明质酸或其药学上可接受的盐的稳定液体药学组合物及其制造方法 | |
| ES2679279T3 (es) | Composiciones farmacéuticas inyectables para el tratamiento de las articulaciones | |
| US11564910B2 (en) | Drug compositions | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| CO6270207A2 (es) | Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]metil]fenil-2e-2-propenamida y procedimientos para su preparacion | |
| ES2553107T3 (es) | Composición anti-inflamatoria basada en compuestos de estroncio | |
| UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) | |
| ES2704229T3 (es) | Agonistas selectivos del receptor AT2 para su uso en el tratamiento de la caquexia | |
| TW201023879A (en) | Method of inhibiting and/or rescuing cell terminal differentiation, and composition for treating and/or inhibiting arthritis | |
| ITMI20061932A1 (it) | Complessi a trasferimento di carica per uso medicale | |
| CN103301118A (zh) | 注射用精氨酸布洛芬组合物 | |
| US20240173324A1 (en) | Combinatory therapy for preventing, inhibiting, treating, or reducing aneurysms | |
| MX2008010394A (es) | Tratamientos antivirales intravenosos. | |
| EP4301370A1 (en) | Combinatory therapy for preventing, inhibiting, treating, or reducing aneurysms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |